MRS-1706: Difference between revisions
CSV import Tag: Reverted |
No edit summary Tag: Manual revert |
||
| Line 57: | Line 57: | ||
{{antineoplastic-drug-stub}} | {{antineoplastic-drug-stub}} | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
Latest revision as of 00:40, 17 March 2025
| Chemical Compound | |
|---|---|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider ID | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Properties | |
| Chemical Formula | |
| Molar Mass | |
| Appearance | |
| Density | |
| Melting Point | |
| Boiling Point | |
| Hazards | |
| GHS Pictograms | [[File:|50px]] |
| GHS Signal Word | |
| GHS Hazard Statements | |
| NFPA 704 | [[File:|50px]] |
| References | |
MRS-1706 is a selective inverse agonist for the adenosine A2B receptor.<ref>Li Q, Ye K, Blad CC, den Dulk H, Brouwer J, Ijzerman AP, Beukers MW. ZM241385, DPCPX, MRS1706 are inverse agonists with different relative intrinsic efficacies on constitutively active mutants of the human adenosine A2B receptor. Journal of Pharmacology and Experimental Therapeutics. 2007 Feb;320(2):637-45. </ref> It inhibits release of interleukins and has an antiinflammatory effect.<ref>Vazquez JF, Clement HW, Sommer O, Schulz E, van Calker D. Local stimulation of the adenosine A2B receptors induces an increased release of IL-6 in mouse striatum: an in vivo microdialysis study. Journal of Neurochemistry. 2008 May;105(3):904-9. </ref><ref>Ryzhov S, Zaynagetdinov R, Goldstein AE, Novitskiy SV, Dikov MM, Blackburn MR, Biaggioni I, Feoktistov I. Effect of A2B adenosine receptor gene ablation on proinflammatory adenosine signaling in mast cells. Journal of Immunology. 2008 Jun 1;180(11):7212-20. </ref>
References[edit]
<references group="" responsive="1"></references>



